WeVote

Bill

Bill

HB 96

An Act relating to licensing and registration requirements for certain wholesale drug distributors; and providing for an effective date.

33rd Legislature (2023-2024) Introduced by Mike Prax

Alaska bill streamlines wholesale drug distributor licensing to reduce regulatory burden while maintaining pharmaceutical supply chain oversight and consumer safety protections.

(H) REFERRED TO LABOR & COMMERCE
0
WeVote Research Nonpartisan
Bill Summary · HB 96

Legislative bill overview

HB 96 modifies Alaska's licensing and registration requirements for wholesale drug distributors, streamlining regulatory oversight of entities that supply medications to pharmacies, hospitals, and other healthcare facilities. The bill received a committee substitute from the Health and Social Services Committee and was referred to Labor & Commerce for further consideration.

Why is this important

Wholesale drug distributors are critical infrastructure in pharmaceutical supply chains. Changes to their licensing requirements can affect medication availability, pricing, and the state's ability to prevent counterfeit or diverted drugs from entering the market. Regulatory efficiency must be balanced against adequate consumer protections and drug safety oversight.

Potential points of contention

  • Scope of deregulation: Whether streamlined requirements reduce unnecessary bureaucratic burden or compromise the state's ability to monitor pharmaceutical supply chain integrity and prevent drug diversion
  • Public health safeguards: Whether modified licensing standards maintain sufficient oversight to detect and prevent distribution of counterfeit, expired, or improperly stored medications
  • Small business impact: How changes affect independent distributors versus large pharmaceutical companies, and whether they level or tilt the competitive playing field

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.